Risperdal Male Breast Development Lawsuits

Manufactured by Johnson & Johnson/Janssen Pharmaceuticals, Risperdal was initially approved a decade ago for use by children and teenagers.

However, Johnson & Johnson promoted Risperdal for the youth years before its approval, with deleterious effects, for use in young people.

Risperidone, or Risperdal, can result in young boys developing female breast tissue, which is known as the gynecomastia condition.

To add insult to injury, Johnson & Johnson did not ensure labels for Risperdal warned of risks for gynecomastia, despite advice from physicians to achieve this.

The evidence is strong that Johnson & Johnson was aware of gynecomastia risks. However, from the FDA, the stalwart company manipulated information and withheld major evidence.

Several years ago, the United States Justice Department fined Johnson & Johnson over $2 billion for illegally marketing Risperdal.

Risperdal male breast development lawsuits are being fined throughout the United States against Johnson & Johnson. It has been alleged that the makers of Risperdal were aware of the risks involving gynecomastia, but neglected to warn consumers.

Millions of dollars have been settled in a majority of these legal cases.

Gynecomastia is often linked to a hormone imbalance, and can cause male breasts to grow, and immense weight gain.

Many believe that Risperdal, in several male youth users, may result in gynecomastia due to an increase in hormone prolactin levels, which can stimulate lactation and female breast development.

Studies have confirmed that Risperidone should be taken with caution by young patients.

The association of Risperdal to Gynecomastia became newsworthy from a study more than a decade ago by a psychiatrist who discovered a correlation between Risperdal and gynecomastia in young boys and teenagers.

Research concluded that during administering Risperidone for psychotic symptoms to adolescents, the medication can boost levels of prolactin, which can result in outcomes, such as gynecomastia.

The marketing campaign was illegal, egregious and dangerous considering that Johnson & Johnson concealed crucial safety information simultaneously regarding adverse effects of Risperdal.

Information from recent studies confirm that Risperdal can present an increase in risk of the gynecomastia condition, in which young males develop breast tissue due to hormone prolactin production.

These test results were concealed from physicians, patients, and the U.S. Food and Drug Administration by Johnson & Johnson.

Those with the gynecomastia condition sustain critical psychological trauma, and at times, to remove a excess in breast tissue, require surgical intervention.

Journal of Child and Adolescent Psychopharmacology studies conclude a strong association between the use of Risperidone, and young adults suffering from gynecomastia.

Children and teen users of Risperidone, compared to non-users, were discovered to have a risk of gynecomastia that was higher (5x).

Thus, there is a psychological burden that is high related to gynecomastia, according to studies.

Many individuals are filing Risperdal male breast development lawsuits against Johnson & Johnson due to sustaining unforeseen drug side effects.

You may be entitled to a lawsuit to recover compensation for healthcare bills, lost wages, suffering and pain, etc.

It takes a personal injury medical malpractice attorney to determine if you meet the criteria for eligibility.

Contact us for a free consultation or call Anzalone Law Firm PLLC, at: 603.548.3797.